EGFR and lung cancer: We revealed that the combined treatment with AT-101 and gefitinib induced additional cell death in vitro and in vivo, overcame the acquired resistance to EGFR TKIs in T790M mutant lung cancer, and that cell death is mediated through inhibition of bcl-2, downregulation of phosphorylation of EGFR, Akt, and Erk and induction of cell apoptosis.